Novacyt S.A. is an international molecular diagnostics company specializing in the development, manufacture, and commercialization of molecular assays, workflows, and instrumentation for research and clinical applications. Primarily focused on delivering genomic medicine, it offers integrated technologies and services across human health, animal health, and environmental sectors, with leadership in reproductive health, precision medicine, infectious diseases, and cancer diagnostics. Key business units include Primerdesign, renowned for qPCR kits and reagents since 2005; Yourgene Health, acquired in 2023, providing non-invasive prenatal testing (NIPT), next-generation sequencing workflows, and Ranger® Technology for cell-free DNA analysis; Microgen Bioproducts; and Lab21 Healthcare. Novacyt S.A. supplies in vitro diagnostic tests and reagents worldwide, notably contributing COVID-19 testing solutions approved by the WHO in 2020. Headquartered in Le Vésinet, France, with offices in the UK, US, Canada, Singapore, and commercial presence in over 65 countries, it employs around 237 people and plays a vital role in advancing precise diagnostic solutions through innovation and global partnerships.